Plain-English translation of NCT06413433 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This research study is testing whether a medication called solriamfetol can help people with binge eating disorder reduce how often they binge eat. The study will compare two different doses of the medication against a placebo (a pill with no active ingredient) to see which works best and is safest. About 450 adults will participate over 12 weeks.
Binge eating disorder is a serious condition that affects how people eat and their overall health, but treatment options are limited. Researchers believe this medication may help by affecting brain chemicals involved in eating behavior, and this trial will test whether that approach actually works.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to take either the lower dose of the medication, the higher dose, or a placebo once each day for 12 weeks. You won't know which group you're in (that's the "double-blind" part). You'll need to come to study visits so researchers can check how you're doing, ask about your eating patterns, and make sure the treatment is safe for you.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States